People · Operator
Named in public records as an officer, director or promoter · active 2014–2022 · Pharma, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Indapta Therapeutics Inc. | — | Pharma | Series C | $84.4M | $289.6M | 2022 |
| Chrono Therapeutics Inc. | — | Other Health Care | Series B | $51.4M | $833.2M | 2014 |
GUY DIPIERRO at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside GUY DIPIERRO on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Alan Levy | 1 | 7 |
| Ronald Martell | 1 | 4 |
| Alan Levy, Ph.D. | 1 | 3 |
| Lori Hu | 1 | 3 |
| Mark Frohlich | 1 | 3 |
| JAMES W. YOUNG | 1 | 3 |
| WENDE W. HUTTON | 1 | 2 |
| Fabio Pucci | 1 | 2 |
| ANTHONY RIMAC | 1 | 2 |
| Laura Stoppel | 1 | 1 |
| TIM W. KILGALLON | 1 | 1 |
| STEVEN W. JAMES | 1 | 1 |
| GUY W. DIPIERRO | 1 | 1 |
| ELIZABETH W. ROCKETT | 1 | 1 |
| AIDAN W. KING | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.